The reasons for this resistance include lack of CD8+ T cells associated with endogenous oncogenic activation of the WNT-β-catenin pathway in melanoma cells (5), lack of PD-1 receptors, mutation and antigen presentation of tumor antigen, dynamic changes of immune microenvironment, genetic mutations, and epigenetic changes in essential tumor proteins (6). The gene discussed is CD8A; the disease is melanoma.